We found that SEC62 positivity of tumor cells in pre-therapeutic samples was a significant and independent prognostic factor indicating a shorter overall survival and significantly correlated with advanced lymph node metastases, p16 positivity, and chronic tobacco exposure. This evidence concerns the gene SEC62 and neoplasm.